MIVT Commences Animal Trials of SagaX's Stroke-Preventing Device

MIV Therapeutics (MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has announced commencement of preclinical trials of a unique proprietary filtration device designed to be implanted in a main artery during cardiac procedures and heart surgery to divert particles that might otherwise reach the brain and cause strokes. The device was developed by SagaX Medical Technologies, a company recently acquired by MIVT.

MENAFN (http://menafn.com/qn_news_story.asp?StoryId=CqOqMqbKbmtmZyJeXnJG)